BRCA1 and ovarian carcinoma: The PARP inhibitor olaparib (LynparzaTM, also known as AZD2281) is approved for ovarian cancer with germline BRCA1/2 mutations in the US and EU, and for somatic BRCA1/2 mutations in the EU only.